Carlsmed revenue rises 98% to $13.1 million in third quarter 2025

Reuters

2025/11/07

Carlsmed revenue rises 98% to $13.1 million in third quarter 2025

Carlsmed Inc. reported third quarter 2025 revenue of $13.1 million, a 98% increase from $6.6 million in the same period last year. Gross profit reached $9.9 million with a gross margin of 75.9%, compared to $4.8 million and 72.8% in the third quarter of 2024. Operating expenses rose to $19.0 million from $12.6 million, with research and development expenses at $4.4 million and sales and marketing expenses at $9.6 million. The company raised its full-year 2025 revenue guidance to $49 million-$50 million. Recent business developments include a reduction in lead time for aprevo interbody implants to eight business days and securing NTAP reimbursement for cervical procedures, with more than 50 patients treated in a clinical evaluation. Carlsmed plans to launch its cervical spine platform early next year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Carlsmed Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570809-en) on November 06, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2581918017"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581918017\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581918017?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581918017","market":"us","top_or_hot":-1,"title":"Carlsmed revenue rises 98% to $13.1 million in third quarter 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Carlsmed revenue rises 98% to $13.1 million in third quarter 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Carlsmed Inc. reported third quarter 2025 revenue of $13.1 million, a 98% increase from $6.6 million in the same period last year. Gross profit reached $9.9 million with a gross margin of 75.9%, compared to $4.8 million and 72.8% in the third quarter of 2024. Operating expenses rose to $19.0 million from $12.6 million, with research and development expenses at $4.4 million and sales and marketing expenses at $9.6 million. The company raised its full-year 2025 revenue guidance to $49 million-$50 million. Recent business developments include a reduction in lead time for aprevo interbody implants to eight business days and securing NTAP reimbursement for cervical procedures, with more than 50 patients treated in a clinical evaluation. Carlsmed plans to launch its cervical spine platform early next year.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Carlsmed Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570809-en) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Carlsmed revenue rises 98% to $13.1 million in third quarter 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCarlsmed revenue rises 98% to $13.1 million in third quarter 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 05:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Carlsmed revenue rises 98% to $13.1 million in third quarter 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Carlsmed Inc. reported third quarter 2025 revenue of $13.1 million, a 98% increase from $6.6 million in the same period last year. Gross profit reached $9.9 million with a gross margin of 75.9%, compared to $4.8 million and 72.8% in the third quarter of 2024. Operating expenses rose to $19.0 million from $12.6 million, with research and development expenses at $4.4 million and sales and marketing expenses at $9.6 million. The company raised its full-year 2025 revenue guidance to $49 million-$50 million. Recent business developments include a reduction in lead time for aprevo interbody implants to eight business days and securing NTAP reimbursement for cervical procedures, with more than 50 patients treated in a clinical evaluation. Carlsmed plans to launch its cervical spine platform early next year.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Carlsmed Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570809-en) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CARL","symbol_name":"Carlsmed, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDLcb8wDd:1","article_id":"2581918017","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581918017","pubTimestamp":1762462899,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Carlsmed Inc. reported third quarter 2025 revenue of $13.1 million, a 98% increase from $6.6 million in the same period last year. Gross profit reached $9.9 million with a gross margin of 75.9%, compared to $4.8 million and 72.8% in the third quarter of 2024. Operating expenses rose to $19.0 million from $12.6 million, with research and development expenses at $4.4 million and sales and marketing expenses at $9.6 million. The company raised its full-year 2025 revenue guidance to $49 million-$50 million. Recent business developments include a reduction in lead time for aprevo interbody implants to eight business days and securing NTAP reimbursement for cervical procedures, with more than 50 patients treated in a clinical evaluation. Carlsmed plans to launch its cervical spine platform early next year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated co","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CARL":"Carlsmed, Inc.","BK4082":"医疗保健设备","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所","BK4112":"金融交易所和数据","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4585":"ETF&股票定投概念"},"translate_title":"CarlsMed 2025年第三季度收入增长98%至1310万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CARL":0.9,"NDAQ":0.9},"content_text":"Carlsmed revenue rises 98% to $13.1 million in third quarter 2025\n    \n\n        Carlsmed Inc. reported third quarter 2025 revenue of $13.1 million, a 98% increase from $6.6 million in the same period last year. Gross profit reached $9.9 million with a gross margin of 75.9%, compared to $4.8 million and 72.8% in the third quarter of 2024. Operating expenses rose to $19.0 million from $12.6 million, with research and development expenses at $4.4 million and sales and marketing expenses at $9.6 million. The company raised its full-year 2025 revenue guidance to $49 million-$50 million. Recent business developments include a reduction in lead time for aprevo interbody implants to eight business days and securing NTAP reimbursement for cervical procedures, with more than 50 patients treated in a clinical evaluation. Carlsmed plans to launch its cervical spine platform early next year.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Carlsmed Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570809-en) on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}